$200M investment to advance clinical programs for Ambrx
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
Monte Rosa raises $96M Series B for drug development platform technology
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Karius, using liquid biopsy to detect infectious diseases, raises $165M in Series B round
The SoftBank Vision Fund led the round, which the company said would be used t expand its reach and support future clinical studies.
ALX Oncology raises $105M in Series C round for checkpoint inhibitor development
The company is working to move its CD47-targeting drug, ALX148, into Phase II development. Another company, Forty Seven, is also developing a CD47-targeting therapy. CD47 is an immune checkpoint distinct from the ones targeted by currently marketed cancer immunotherapy drugs.
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
Galera Therapeutics raises $150M Series C round to fund clinical development
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.